Pathogenetic role of phagocytic abnormalities in human virus immunodeficiency infection: Possible therapeutical approaches. A review

Immunopharmacology and Immunotoxicology

Volumn 19, Issue 2, 1997, Pages 147-164

  Covelli, Vito ^a   Pece, Salvatore ^b   Giuliani, Giuseppe ^b   De Simone, Claudio ^c   Jirillo, Emilio ^b,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

^d POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BARTONELLA HENSELAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOCYTE; NEUTROPHIL; OPPORTUNISTIC INFECTION; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; RHODOCOCCUS;

EID: 0030997079     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979709007655     Document Type: Review

References (76)

1. Stanley, S.K., Fauci, A.S. Acquired immunodeficiency syndrome, in Clinical Immunology: Principles and Practice, edited by R.R. Rich (editor-in-chief), p.707, Mosby-Year Book, Inc., ST. Louis, 1996.
2. Heltler, M.S., Skillman, D.R., Hoover, D.L. et al., Macrophages and the human immunodeficiency virus, Immunol. today, 11: 247, 1990.
3. Poli, G., Fauci, A.S. The role of monocyte/macrophages and cytokines in the pathogenesis of HIV infection, Pathobiology, 60:246,1992.
4. Lazzarin, A., Uberti Foppa, C., Galli, M. et al. Impairment of polymorphonuclear leukocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome, Clin.Exp.Immunol. 65:105, 1986.
5. Antonaci, S., Jirillo, E., Stasi, D. et al. Immunoresponsiveness in hemophilia: lymphocyte and phagocyte-mediated functions, Diagn.Clin.Immunol., 5: 318, 1988.
6. Retini, C., Vecchiarelli, A., Monari, C. et al. Capsular lipopolysaccharide of Cryptococcus neoformans induce proinflammatory cytokine release by human neutrophils. Infect.Immun., 64: 2897, 1996.
7. Lafrenie, R.M., Wahl, L.M., Epstein, J.S., et al., HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes, J.Immunol., 157:974, 1996.
8. Bloom, B.R., Murray, C.J.L., Tuberculosis: commentary on reemergent killer, Science, 257: 1055, 1992.
9. Horsburgh, C.R.Jr. Mycobacterium avium complex infection in the Acquired Immunodeficiency Syndrome, N.Engl.J.Med., 324: 1332,1991.
10. Pece, S., Giuliani, G., Fumarola, D., et al., Mechanisms of immunoresponsiveness against emerging intracellular bacteria, Med.Sci.Res., 24: 435, 1996.
11. Harrison, T.S., Levitz, S.M., Role of IL-12 peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection, J.Immunol., 156: 4492, 1996.
12. Mosmann, T., Cytokines and immunoregulation, in Clinical Immunology: Principles and Practice, Edited by R.R. Rich (editor-in-chief), p.217, Mosby -Year Book, Inc., St. Louis, 1996.
13. Flesch, I.E.A., Hess, J.H., Huang, S., et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon-γ and tumor necrosis factor-α, J.Exp.Med., 181: 1615, 1995.
14. Jirillo, E., Pellegrino, N.M., Antonaci, S., Role of tumor necrosis factor-α in physiological and pathological conditions, Med.Sci.Res., 23: 75, 1995.
15. Doherty, T.M., Interleukin-13. A review, EOS J.Immunol.Immunopharmacol., 15: 81, 1995.
16. Finnegan, A., Roebuck, K.A., Nakai, B.E., et al., IL-10 cooperates with TNF-α to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage, J.Immunol., 156: 841, 1996.
17. Yoo, J., Chen, H., Kraut, T., et al., Altered cytokine production and accessory cell function after HIV-1 infection, J.Immunol., 157: 1313, 1996.
18. Harvey, R.L., Sunstrom, J.C., Rhodococcus equi infection in patients with and without human immunodeficiency virus infection, Rev.Infect.Dis., 13: 139, 1991.
19. Verville, D.T., Slater, N.L., et al., Rhodococcus equi infections of humans: 12 cases and review of the literature, Medicine, 73: 119, 1994.
20. Giuliani, G., Pece, S., Modeo, G., et al., In vitro infection with Rhodococcus equi: cytokine release and phagocytic functions by normal and HIV-positive human macrophages, J.Leuk.Biol., Abstr. 270, p.58, Suppl.1996.
21. Nordmann, P., Ronco, E., Guenounou, M., Involvement of interferon-γ and tumor necrosis factor-α in host defense against Rhodococcus equi, J.Infect.Dis., 167: 1456, 1993.
22. D'Elia, S., Mastroianni, C.M., Lichtner, M., et al., Defective production of interferon-γ and tumor necrosis factor-α by AIDS mononuclear cells after in vitro exposure to Rhodococcus equi, Med.Inflamm., 4: 306, 1995
23. Pece, S., Fumarola, D., Giuliani, G., Jirillo, E. et al., Phagocytosis and killing of Rhodococcus equi by normal and HIV-positive human macrophages, 96th ASM Meeting, New Orleans, May, 19-23, p.181, 1996, Abstr.B-155.
24. Prescott, J.F., Rhodococcus equi: an animal and human pathogen, Clin.Microbiol.Rev. 4: 20, 1991.
25. Adal, A.K., Cockerel, J.C., Petri, A.W., Current concepts: Cat Scratch Disease, Bacillary Angiomatosis, and other infectoins due to Rochalimaea. N.Engl.J.Med., 330: 1509, 1994.
26. Regnery, R.L., Anderson, B.E., Clarridge III, J.E., Characterization of a novel Rochalimaea species, R. henselae sp.nov. isolated from blood of a febrile human immunodeficiency virus-positive patient, J.Clin.Microbiol., 30: 265, 1992.
27. Zbinden, R., Hochli, M., Nadal, D., Intracellular location of Bartonella henselae cocultivated with vero cells and used for an indirect fluorescent-antibody test, Clin.Diagn.Lab.Immunol., 2: 693, 1995.
28. Fumarola, D., Pece, S., Fumarulo, R., et al., Downregulation of human polymorphonuclear cell activities exerted by microorganisms belonging to α-2 subgroup of Proteobacteria (Afipia felis and Rochalimaea henselae). Immunopharmacol. Immunotoxicol., 16: 449, 1994.
29. Pece, S., Maffione, A.B., Petruzzelli, R., et al., Rochalimaea henselae organisms possess an elevated capacity of binding to peripheral blood lymphocytes from patients with Cat Scartch Disease. Microbios, 77: 95, 1994.
30. Fumarola, D., Giuliani, G., Pece, S., et al., Pathogenicity of cat-scratch disease bacilli, Ped.Infect.Dis.J., 13. 162,1994.
31. Fumarola, D., Pece, S., Giuliani, G., et al., Induction of human macrophage and endothelial cell oxidative burst and activity in the Limulus amebocyte lysate assay by different Bartonella henselae LPS preparations, J.Endotox.Res., 1996, in press.
32. Jirillo, E., Greco, B., Munno, I., et al., Demonstration of an exagerated serum release of tumor necrosis factor-α and interleukin-1β in HIV-infected patients: a possible correlation with circulating levels of bacterial lipopolysaccharides, in Cellular and Molecular Aspects of Endotoxin Reactions, Edited by A. Nowotny, J.J. Spitler, E.J. Ziegler, p.529, Elsevier Science Publishers, B.U. (Biomedical Division), Amsterdam, 1990.
33. Jirillo, E., Covelli, U., Maffione, A.B. et al., Endotoxins, cytokines, and neuroimmune networks with special reference to HIV infection, Ann.N.Y.Acad. Sci. 741: 174,1994.
34. Collier, A.C., Marra, C., Coombs, R.W. et al., Central nervous system manifestations in human immunodeficiency virus infection without AIDS, J.Acquir.Immune Defic.Syndr., 5: 229, 1992.
35. Epstein, L.G., Gendelman, H.E., Human immunodeficiency viru type 1 infection on the nervous system: pathogenic mechanisms, Ann.Neurol., 33: 429, 1993.
36. Ho, D.D., Bredesen, D.E., Vinters, H.U. et al., The acquired immunodeficiency syndrome (AIDS) dementia complex, Ann.Intern.Med., 111: 400, 1989.
37. Pulliam, L., Herndier, B.G., Jong, N.M. et al., Human immunodeficiency virus-infected macrophage produce soluble factors that cause histological and neurochemical alterations in cultured human brains, J.Clin.Invest., 87: 503, 1991.
38. Nottet, H.S.L., Genhelman, H.E., Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex, Immunol.Today, 16: 441, 1995.
39. Bradl, M., Immune control of the brain, Springer Semin.Immunopathol., 18: 35, 1996.
40. Mastroianni, C.M., Liuzzi, G.M., Jirillo, E. et al., Cerebrospinal fluid markers for the monitoring of HIV dementia complex severity: usefulness of anti-myelin basic protein antibody detection, AIDS, 5: 464, 1991.
41. Mastroianni, C.M., Liuzzi, G.M., Vullo, V. et al., Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia complex, Molec.Chem.Neuropathol., 14: 227, 1991.
42. Mastroianni, C.M., Paoletti, F., Valenti, C. et al., Tumor necrosis factor (TNF-α) and neurological disorders in HIV infection, J.Neurol.Neurosurg.Psychiat., 55: 49, 1992.
43. Liuzzi, G.M., Mastroianni, C.M., Vullo, V. et al., Cerebrospinal fluid myelin basic protein as a predective marker of demyelination in HIV dementia complex, J.Neuroimmunol., 36: 251, 1992.
44. De Simone, C., Maffione, A.B., Calvello, R. et al., In vitro effects of 3'-azido-3'-deoxitimidine (AZT) on normal human polymorphonuclear cell and monocyte/macrophage functional capacities, Immunopharmacol.Immunotoxicol., 18: 161, 1996.
45. Moore, M., The clinical use of colony stimulating factors, Ann.Rev.Immunol., 9: 159, 1991.
46. Mitsuyasu, R.T., Use of recombinant interferons and hematopoietic growth factors in patients infected with human immunodeficiency virus, Rev:Infect.Dis., 13: 979, 1991.
47. Mueller, B.U., Jacobsen, F., Butler, K.M., et al. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection, J.Pediatr., 121: 797, 1992.
48. Green, S.J., Turpin, J.A., Nancy, C.A., Cytotoxic effector activities of macrophages, in Clinical Immunology: Principles and Practice, Edited by R.R. Rich (editor-in-chief) p.290, Mosby-Year Book, Inc., St.Louis, 1996.
49. Jirillo, E., De Candia, P., Ribaud, M.R., et al., Enhancement of polymorphomuclear cell phagocytosis by lipid A-activated monocytes via cell-to-cell contact. A possible role for membrane-associated cytokines, Immunopharmacol. Immunotoxicol., 14: 343, 1992.
50. De candia, P., Serrone, M., Pestillo, L. et al., Enhancement of plymorphonuclear cell phagocytosis by lipid-A activated monocytes via cell-to-cell contact: a possible role for membrane-associated interleukin-6 and interleukin-8, Immunopharmacol.Immunotoxicol., 17: 49, 1995.
51. De Simone, C., Famularo, G., Cifone, G. et al., HIV-infections and cellular metabolism, Immunol. Today, 17: 256, 1996.
52. Rivas, C.I., Golde, D.W., Vera, J.C. et al., Involvement of the sphingomyelin pathway in autocrine tumor necrosis factor signaling for human immunodeficiency virus production in chronically infected HL-60 cells, Blood, 83: 2191, 1994.
53. De Simone, C., Cifone, G., Alesse, E. et al., Cell-associated ceramide in HIV-1 infected subjects, AIDS, 1996.
54. De Simone, C., Tzantzoglov, S., Jirillo, E. et al., L-carnitine deficiency in AIDS patients, AIDS 6: 203, 1992.
55. Famularo, G., De Simone, C., Arrigoni Martelli, E. et al., Carnitine and septic shock: a review, J.Endotox.Res. 2: 141, 1995.
56. De Simone, C., Tzantzoglov, S., Santini, G. et al., Clinical and immunological effects of combination therapy with intravenous immunoglobulins and AZT in HIV-infected patients, Immunopharmacol.Immunotoxicol., 13: 447, 1991.
57. Takai, S., Masayuki, I., Noboru, T., Suppression of tumor necrosis factor α production by a human immunoglobulin preparation for intravenous use, Infect.Immun., 5: 1394, 1990.
58. Kalogeras, K.T., Calogero, A.E., Kuribajiashi, T. et al., In vitro and in vivo effect of the trialolobenzodiazepine alprazolam and hypothalamic-pituitary-adrenal function: pharmacological and clinical implications, J.Clin.Endocrinol.Metabol., 70: 1462, 1990.
59. Kim, M., Ferguson-Chanowitz, J.V., Katocs, A.S. et al. Platelet ativating factor or/a platelet-activating factor antagonist decreases tumor necrosis factor-α in the plasma of mice treated with endotoxin, J.Infect.Dis., 162: 1081, 1990.
60. Maffione, A.B., Calvello, R., Greco, B. et al., In vitro effect of alprazolam on TNF-α release from normal human peripheral blood mononuclear cells. A brief definitive report, EOS J.Immunol.Immunopharmacol., 15: 120, 1995.
61. Covelli, V., Maffione, A.B., Greco, B. et al. In vivo effects of alprazolam and lorazepam on the immune response in patients with migraine without aura, Immunopharmacol.Immunotoxicol., 15: 415, 1993.
62. Garau, L., Memo, M., Pizzi, M. et al., Properties of benzodiazepine binding sites in peripheral blood lymphocytes, J.Clin.Lab.Anal., 3: 334, 1989.
63. Jirillo, E., Maffione, A.B., Greco, B. et al., Trialolobenzodiazepines exert immunopotentiating activities on normal human peripheral blood lymphocytes, Immunopharmacol.Immunotoxicol., 15: 307, 1993.
64. Mc Geehan, G.M., Becherer, J.D., Bast, Jr., R.C. et al., Regulation of tumor necrosis factor-α processing by a metallo proteinase inhibitor, Nature, 370: 558, 1994.
65. Rice, G.C., Brown, P.A., Nelson, R.J. et al., Protection from endotoxic shock in mice by pharmacologic inhibition of phosphatidic acid, Proc.Natl.Acad.Sci.Usa, 91: 3857, 1994.
66. Waage, A., Sorensen, M., Stordal, B., Differential effect of oxpentifylline on tumor-necrosis-factor and interleukin-6 production, Lancet, 335: 543, 1990.
67. Covelli, V., Munno, I., Pellegrino, N.M. et al., In vivo administration of propranolol decreases exaggeraed amount of serum TNF-α in patients with migraine without aura, Acta Neurol., 14: 313, 1992.
68. Strieter, R.M., Standiford, T.J., Huffnagle, G.B. et al., "The good, the bad, and the hugly". The role of chemokines in models of human disease, J.Immunol., 156: 3583, 1996.
69. Huffnagle, G.B., Strieter, R.M., Standiford, T.J. et al., The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Criptococcus neoformans infection, J.Immunol, 155: 4790, 1995.
70. + T cells, Science, 270: 1811, 1995.
71. Editorial, LCF gets ok as il-16 but doubt remains, Immunol.Today, 17: 250, 1996.
72. Baier, M.A., Werner, N., Bannert, W. et al., HIV suppression by interleukin-16, Nature, 378: 563, 1995.
73. Levy, J.A., Mackewicz, C.E., Barker, E., Controlling HIV pathogenesis: the role of monocytotoxic anti-HIV response of CD8(+) T cells, Immunol.Today, 17: 217, 1996.
74. + T cell suppressor activities. Dichotomy between infected and unifected individuals, evolution with progression of disease, and sensitivity to gamma irradiation, J.Immunol., 156: 4476, 1996.
75. Haase, A.T., Pathogenesis of lentivirus infections, Nature, 322: 130, 1986.
76. Lipton, S.A., Rosenberg, P.A., Mechanisms of disease: excitatory amino acids as a final common pathway for neurologic disorders, New Engl.J.Med., 330: 613, 1994.